Cancer Research and Treatment

Original Articles

General

A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy: Young-Woong Won, Jin-Hyoung Kang, Jung Hye Kwon, Dong-Hoe Koo, Jung Hun Kang, Chi Hoon Maeng, Hee Kyung Ahn, Sung Yong Oh, Dae-Won Lee, Joohyuk Sohn, So Yeon Oh, Kyung Hee Lee, Su-Jin Koh, Keun Seok Lee, Chan-Kyu Kim, Ji-Yeon Kim, Jun Ho Ji, Sung-Bae Kim, Joo Young Ha, Ho Young Kim; Cancer Res Treat. 2023;55(4):1096-1103. Published online April 7, 2023; DOI: https://doi.org/10.4143/crt.2022.1565

Abstract PDF Supplementary Material PubReader ePub

Purpose
Several previous studies and case reports have reported ethanol-induced symptoms in patients receiving anticancer drugs containing ethanol. Most docetaxel formulations contain ethanol as a solvent. However, there are insufficient data on ethanol-induced symptoms when docetaxel-containing ethanol is administered. The primary purpose of this study was to investigate the frequency and pattern of ethanol-induced symptoms during and after docetaxel administration. The secondary purpose was to explore the risk factors for ethanol-induced symptoms.
Materials and Methods
This was a prospective, multicenter, observational study. The participants filled out ethanol-induced symptom questionnaire on the day of chemotherapy and the following day.
Results
Data from 451 patients were analyzed. The overall occurrence rate of ethanol-induced symptoms was 44.3% (200/451 patients). The occurrence rate of facial flushing was highest at 19.7% (89/451 patients), followed by nausea in 18.2% (82/451 patients), and dizziness in 17.5% (79/451 patients). Although infrequent, unsteady walking and impaired balance occurred in 4.2% and 3.3% of patients, respectively. Female sex, presence of underlying disease, younger age, docetaxel dose, and docetaxel-containing ethanol amount were significantly associated with the occurrence of ethanol-induced symptoms.
Conclusion
The occurrence of ethanol-induced symptoms was not low in patients receiving docetaxel-containing ethanol. Physicians need to pay more attention to the occurrence of ethanol-induced symptoms and prescribe ethanol-free or low-ethanol-containing formulations to high-risk patients.

Citations

Citations to this article as recorded by

Ethanol intoxication in paediatric patients receiving intravenous etoposide as conditioning regimen for allogenic hematopoietic stem cell transplant
Pauline Claraz, Marie de Tersant, Valentine Feyants, Julie Roupret-Serzec, Thomas Storme, Jean-Hugues Dalle
Journal of Oncology Pharmacy Practice.2025;[Epub] CrossRef
Self-assembled leuprolide-oleic acid nanoparticles encapsulating docetaxel for synergistic drug delivery
Jeongro Lee, Hy Dinh Nguyen, Sura Saad Abdullah, Raimar Löbenberg, Beom-Jin Lee
International Journal of Pharmaceutics.2025; 685: 126235. CrossRef
Evaluation of self-assembling properties of paclitaxel-biotin conjugates
Dmitry V. Beigulenko, Anna Yu. Belyaeva, Ekaterina S. Kazakova, Maria M. Antonova, Aleksander S. Peregudov, Aleksey A. Nikitin, Tatyana S. Kovshova, Yulia V. Ermolenko, Konstantin A. Kochetkov
Nano-Structures & Nano-Objects.2024; 40: 101375. CrossRef

5,497 View
226 Download
3 Web of Science
3 Crossref

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies: Myung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, Byoung Chul Cho, Jin-Hyoung Kang, Sang-We Kim, James Chih-Hsin Yang, Tetsuya Mitsudomi, Jong Seok Lee; Cancer Res Treat. 2020;52(1):284-291. Published online July 23, 2019; DOI: https://doi.org/10.4143/crt.2019.200

Abstract PDF PubReader ePub

Purpose
Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system (CNS) metastases. We present results of a subgroup analysis of Korean patients from the pooled data of two global phase II trials: AURA extension (NCT01802632) and AURA2 (NCT02094261).
Materials and Methods
Enrolled patients had EGFR T790M-positive NSCLC and disease progression during or after EGFR-TKI therapy. Patients received osimertinib 80 mg orally once daily until disease progression. The primary endpoint was objective response rate (ORR).
Results
In total, 66 Korean patients received osimertinib treatment with a median treatment duration of 19 months. In the evaluable-for-response population (n=62), ORR was 74% (95% confidence interval [CI], 61.5 to 84.5) and median duration of response was 9.8 months (95% CI, 7.1 to 16.8). In the full analysis set (n=66), median progression-free survival was 10.9 months (95% CI, 8.3 to 15.0; data cutoff November 1, 2016), and median overall survival was 29.2 months (95% CI, 24.8 to 35.7; data cutoff May 1, 2018). Eight patients with CNS metastases were evaluable for response, none of whom showed CNS progression. The most common adverse events were rash (53%), cough (33%), paronychia, diarrhea, and decreased appetite (each 32%).
Conclusion
Efficacy and safety profiles of osimertinib in this subgroup are consistent with the global phase II pooled population, which supports osimertinib as a recommended treatment for Korean patients with T790M positive NSCLC.

Citations

Citations to this article as recorded by

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer
S.-H. Lee, J. Menis, T.M. Kim, H.R. Kim, C. Zhou, S.A. Kurniawati, K. Prabhash, H. Hayashi, D.D.-W. Lee, M.S. Imasa, Y.L. Teh, J.C.-H. Yang, T. Reungwetwattana, V. Sriuranpong, C.-E. Wu, Y. Ang, M. Sabando, M. Thiagarajan, H. Mizugaki, V. Noronha, M. Yuli
ESMO Open.2024; 9(12): 103996. CrossRef
The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review
Valerio Nardone, Caterina Romeo, Emma D’Ippolito, Pierpaolo Pastina, Maria D’Apolito, Luigi Pirtoli, Michele Caraglia, Luciano Mutti, Giovanna Bianco, Antonella Consuelo Falzea, Rocco Giannicola, Antonio Giordano, Pierosandro Tagliaferri, Claudia Vincigue
La radiologia medica.2023; 128(3): 316. CrossRef
The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China
Mingjun Rui, Zijing Wang, Zhengyang Fei, Yao Wu, Yingcheng Wang, Lei Sun, Ye Shang, Hongchao Li
Frontiers in Pharmacology.2022;[Epub] CrossRef
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial
Anwen Xiong, Shengxiang Ren, Huaimin Liu, Liyun Miao, Lei Wang, Jianhua Chen, Wei Li, Runpu Li, Xiang Wang, Zhiwei Lu, Donglin Wang, Xiaohong Wu, Zhihua Liu, Ligang Xing, Yimin Mao, Chunling Liu, Aiping Zeng, Hongrui Niu, Yingying Du, Yuping Sun, Yueyin P
Journal of Thoracic Oncology.2022; 17(10): 1216. CrossRef
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma
Agnieszka Rybarczyk-Kasiuchnicz, Rodryg Ramlau, Katarzyna Stencel
International Journal of Molecular Sciences.2021; 22(2): 593. CrossRef

11,771 View
317 Download
6 Web of Science
5 Crossref

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13: Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon-Gu Kim, Heui June Ahn, Ha Yeon Lee, Hwan Jung Yun, Jin-Hyoung Kang, Jaeheon Jeong, Moon Young Choi, Sin-Ho Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn; Cancer Res Treat. 2019;51(2):718-726. Published online September 3, 2018; DOI: https://doi.org/10.4143/crt.2018.324

Abstract PDF PubReader ePub

Purpose
The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
Materials and Methods
We conducted a multi-center randomized phase II trial to compare the clinical outcomes between pemetrexed plus cisplatin combination therapy followed by maintenance pemetrexed (PC) and pemetrexed monotherapy (P) after failure of first-line EGFR-TKI. The primary objective was progression-free survival (PFS), and secondary objectives included overall response rate (ORR), overall survival (OS), health-related quality of life (HRQOL), and safety and toxicity profiles.
Results
A total of 96 patientswere randomized, and 91 patientswere treated at 14 centers in Korea. The ORR was 34.8% (16/46) for the PC arm and 17.8% (8/45) for the P arm (p=0.066). With 23.4 months of follow-up, the median PFS was 5.4 months in the PC arm and 6.4 months in the P arm (p=0.114). The median OS was 17.9 months and 15.7 months in PC and P arms, respectively (p=0.787). Adverse events ≥ grade 3 were reported in 12 patients (26.1%) in the PC arm and nine patients (20.0%) in the P arm (p=0.491). The overall time trends of HRQOL were not significantly different between the two arms.
Conclusion
The outcomes of pemetrexed therapy in NSCLC patients with disease progression after firstline EGFR-TKI might not be improved by adding cisplatin.

Citations

Citations to this article as recorded by

The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
Cancer Research and Treatment.2025; 57(1): 39. CrossRef
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial
R.A. Soo, K. Vervita, M. Früh, B.C. Cho, M. Majem, D. Rodriguez Abreu, K. Ribi, A. Callejo, T. Moran, M. Domine Gomez, M. Provencio, A. Addeo, J.Y. Han, A.L. Ortega Granados, M. Reck, A. Blasco, R. Garcia Campelo, M.A. Sala González, C. Britschgi, H. Rosc
Lung Cancer.2025; 202: 108454. CrossRef
Real-world treatment outcomes in South Korean patients with epidermal growth factor receptor-mutant non-small cell lung cancer
Young Saing Kim, Eun Young Lee, Hyun Woo Lee, Jin-Hyuk Choi, Tae-Hwan Kim, Yong Won Choi, Mi Sun Ahn
The Korean Journal of Internal Medicine.2025; 40(6): 1029. CrossRef
Osimertinib with Chemotherapy in EGFR -Mutated NSCLC

New England Journal of Medicine.2024; 390(5): 478. CrossRef
Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors
Balazs Halmos, Pragya Rai, Jae Min, Xiaohan Hu, Diana Chirovsky, Mark Shamoun, Bin Zhao
Frontiers in Oncology.2024;[Epub] CrossRef
Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma
Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
Asia-Pacific Journal of Clinical Oncology.2023; 19(1): 87. CrossRef
Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment
Cheng-Yu Chang, Chung-Yu Chen, Shih-Chieh Chang, Ching-Yi Chen, Yi-Chun Lai, Chun-Fu Chang, Yu-Feng Wei
Frontiers in Oncology.2023;[Epub] CrossRef
Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class
Joseph N. Samuel, Christopher M. Booth, Elizabeth Eisenhauer, Michael Brundage, Scott R. Berry, Bishal Gyawali
JAMA Oncology.2022; 8(6): 879. CrossRef
Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
Ruizhu Sun, Zhansheng Hou, Yankui Zhang, Bo Jiang
Oncology Letters.2022;[Epub] CrossRef
Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid
Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
Lung Cancer.2021; 152: 15. CrossRef
Exploring the role of epidermal growth factor receptor variant III in meningeal tumors
Rashmi Rana, Vaishnavi Rathi, Kirti Chauhan, Kriti Jain, Satnam Singh Chhabra, Rajesh Acharya, Samir Kumar Kalra, Anshul Gupta, Sunila Jain, Nirmal Kumar Ganguly, Dharmendra Kumar Yadav, Timir Tripathi
PLOS ONE.2021; 16(9): e0255133. CrossRef
Risk factors of nephrotoxicity of maintenance pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung
Wang Chun Kwok, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
Lung Cancer.2021; 162: 169. CrossRef
Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
Current Oncology.2021; 28(6): 4894. CrossRef
Real world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma
Wang Chun Kwok, David Chi Leung Lam, Ka Yan Chiang, James Chung Man Ho, Mary Sau Man Ip, Terence Chi Chun Tam
Journal of Chemotherapy.2020; 32(8): 429. CrossRef

12,196 View
360 Download
16 Web of Science
14 Crossref

Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer: Dong-Wan Kim, Hoon-Gu Kim, Joo-Hang Kim, Keunchil Park, Hoon-Kyo Kim, Joung Soon Jang, Bong-Seog Kim, Jin-Hyoung Kang, Kyung Hee Lee, Sang-We Kim, Hun Mo Ryoo, Jin-Soo Kim, Ki Hyeong Lee, Jung Hye Kwon, Jin-Hyuk Choi, Sang Won Shin, Seokyung Hahn, Dae Seog Heo; Cancer Res Treat. 2019;51(1):119-127. Published online March 12, 2018; DOI: https://doi.org/10.4143/crt.2018.019

Abstract PDF Supplementary Material PubReader ePub

Purpose
This randomized phase III study was designed to compare the efficacy and safety of irinote-can plus cisplatin (IP) over etoposide plus cisplatin (EP) in Korean patients with extensive-disease small-cell lung cancer (SCLC).
Materials and Methods
Patients were randomly assigned to receive IP, composed of irinotecan 65 mg/m² intravenously on days 1 and 8+cisplatin 70 mg/m² intravenously on day 1 every 3 weeks, or EP, composed of etoposide 100 mg/m² intravenously on days 1, 2, 3+cisplatin 70 mg/m² intravenously on day 1, every 3 weeks for a maximum of six cycles, until disease progression, or until unacceptable toxicity occurred. The primary endpoint was overall survival.
Results
A total of 362 patients were randomized to IP (n=173) and EP (n=189) arms. There were no significant differences between IP and EP arms for the median overall survival (10.9 months vs. 10.3 months, p=0.120) and the median progression-free survival (6.5 months vs. 5.8 months, p=0.115). However, there was a significant difference in response rate (62.4% vs. 48.2%, p=0.006). The pre-planned subgroup analyses showed that IP was associated with longer overall survival in male (11.3 months vs. 10.1 months, p=0.036), < 65 years old (12.7 months vs. 11.3 months, p=0.024), and Eastern Cooperative Oncology Group performance status 0/1 (12.4 months vs. 10.9 months, p=0.040) patient groups. The severity of treatment-related adverse events such as grade 3/4 anemia, nausea and diarrhea was more frequent in patients treated with IP.
Conclusion
The IP chemotherapy did not significantly improve the survival compared with EP chemotherapy in Korean patients with extensive-disease SCLC.

Citations

Citations to this article as recorded by

Efficacy and tolerability of first-line treatment regimens for extensive-stage small cell lung cancer – a grade-assessed network meta-analysis of randomized controlled trials
Qasi Najah, Hamdy A. Makhlouf, Ahmed S. A. Osman, Nereen A. Almosilhy, Mariam A. Abusalah, Maaly A. Abuhlaiga, Israa Ahmed Qutob, Hussien Ahmed H. Abdelgawad
BMC Cancer.2026;[Epub] CrossRef
A Population Survival Kinetics Assessment of Extensive Small Cell Lung Cancer and Rationale for Maintenance Therapy
David J. Stewart, Katherine Cole, Stephanie Brule
Current Oncology.2025; 32(5): 258. CrossRef
Treatment of small cell lung cancer; advances and future prospects
Seiji Niho
Respiratory Investigation.2025; 63(4): 680. CrossRef
Meta-analysis of surrogate endpoints for overall survival in extensive-stage small-cell lung cancer
S. Durer, P. Fu, Z. Chen, A. Dowlati
ESMO Open.2025; 10(11): 105843. CrossRef
Clinical significance and minimal clinically important differences for the survival outcomes in randomized clinical trials of lung cancer
Yi-Lin Fu, Zi-Yang Tang, Ying-Ying Zhu, Qian-Wen Liu, Meng-Yang Zhang, Cong Gu, Ying Deng, Su Li, Jin-Xin Zhang, Ji-Bin Li
BMC Cancer.2025;[Epub] CrossRef
Factors associated with posttraumatic stress and anxiety among the parents of babies admitted to neonatal care: a systematic review
Reem Malouf, Sian Harrison, Victoria Pilkington, Charles Opondo, Chris Gale, Alan Stein, Linda S. Franck, Fiona Alderdice
BMC Pregnancy and Childbirth.2024;[Epub] CrossRef
Real world results of locally advanced and metastatic lung cancer patients treated with platinum doublet chemotherapy in first line: Moroccan cohort
Hassan Abdelilah Tafenzi, Farah Choulli, Edwin Kelly Haag, Anass Baladi, Ismail Essaadi, Rhizlane Belbaraka
Translational Oncology.2024; 47: 102015. CrossRef
Clinical Benefits of new Systemic Therapy for Small‐Cell Lung Cancer Over Two Decades: A Cross‐Sectional Study
Yuejing Chen, Honghong Liu, Shaohua Bai, Xuejiao Han, Fei Jin, Bo Cui
The Clinical Respiratory Journal.2024;[Epub] CrossRef
Camptothecin and Its Derivatives from Traditional Chinese Medicine in Combination with Anticancer Therapy Regimens: A Systematic Review and Meta-Analysis
Paul O. Odeniran, Paradise Madlala, Nompumelelo P. Mkhwanazi, Mahmoud E. S. Soliman
Cancers.2024; 16(22): 3802. CrossRef
Effect of trilaciclib administered before chemotherapy in patients with extensive-stage small-cell lung cancer: A pooled analysis of four randomized studies
Ying Liu, Lin Wu, Dingzhi Huang, Qiming Wang, Chen Yang, Li Zhou, Shuguang Sun, Xiaomei Jiang, Ying Cheng
Cancer Treatment and Research Communications.2024; 42: 100869. CrossRef
Efficacy and toxicity profile of first‐line treatment for extensive‐stage small cell lung cancer: A Bayesian network meta‐analysis
Guo Lin, Zhuoran Yao, Kai Kang, Hui Wang, Ren Luo, You Lu
Cancer Medicine.2023; 12(9): 10230. CrossRef
Therapeutic strategy analysis of patients with advanced stage high‐grade neuroendocrine cervical cancer: A real‐world multicenter study
Yuanyuan Zhang, Yi Huang, Suiyu Luo, Lin Li, Hongying Yang, Ziyi Wang, Yongmei Peng, Manni Huang, Jusheng An, Xi Yang, Jing Wang, Chunmei Li, Lingying Wu
International Journal of Gynecology & Obstetrics.2022; 158(3): 722. CrossRef
Systematic evaluation of the efficacy‐effectiveness gap of systemic treatments in extensive disease small cell lung cancer
Christine M. Cramer‐van der Welle, Franz M. N. H. Schramel, Bas J. M. Peters, John W. G. van Putten, Olaf H. Klungel, Harry J. M. Groen, Ewoudt M. W. van de Garde
Pharmacoepidemiology and Drug Safety.2021; 30(4): 445. CrossRef
Treatment Outcomes of 9,994 Patients With Extensive-Disease Small-Cell Lung Cancer From a Retrospective Nationwide Population-Based Cohort in the Korean HIRA Database
Jung Soo Lee, Seoree Kim, Soo-Yoon Sung, Yeo Hyung Kim, Hyun Woo Lee, Ji Hyung Hong, Yoon Ho Ko
Frontiers in Oncology.2021;[Epub] CrossRef
Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Tsukasa Ohnishi, Hironori Sagara
Current Oncology.2021; 28(2): 1094. CrossRef
Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study
Seo Ree Kim, Ji Hyung Hong, Soo-Yoon Sung, Yeo Hyung Kim, Sang Hoon Chun, Hyun Woo Lee, Jung Soo Lee, Yoon Ho Ko
BMC Cancer.2021;[Epub] CrossRef
Clinical significance of the cachexia index in patients with small cell lung cancer
Se-Il Go, Mi Jung Park, Gyeong-Won Lee
BMC Cancer.2021;[Epub] CrossRef
Sevens Cases of Neuroendocrine Carcinoma of the Nasal and Paranasal Sinuses
Ichiro Sekine, Kan Kishibe, Miki Takahara, Hiroaki Katada, Tatsuya Hayashi, Yasuaki Harabuchi
Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology).2021; 60(2): 169. CrossRef
Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion
Millie Das, Sukhmani K. Padda, Jared Weiss, Taofeek K. Owonikoko
Advances in Therapy.2021; 38(11): 5431. CrossRef
Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
Current Oncology.2021; 28(6): 4894. CrossRef
Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive‐stage disease small cell lung cancer: Results from a randomized controlled trial
Gyeong‐Won Lee, Se‐Il Go, Dong‐Wan Kim, Hoon‐Gu Kim, Joo‐Hang Kim, Ho Jung An, Joung Soon Jang, Bong‐Seog Kim, Seokyung Hahn, Dae Seog Heo
Thoracic Cancer.2020; 11(1): 62. CrossRef
IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer
Mi-Sook Lee, Kyungsoo Jung, Ji-Young Song, Min-Jung Sung, Sung-Bin Ahn, Boram Lee, Doo-Yi Oh, Yoon-La Choi
Molecular Therapy - Oncolytics.2020; 16: 188. CrossRef
Etoposide and cisplatin versus irinotecan and cisplatin as the first‐line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study
Panpan Zhang, Jie Li, Jian Li, Xiaotian Zhang, Jun Zhou, Xicheng Wang, Zhi Peng, Lin Shen, Ming Lu
Cancer.2020; 126(S9): 2086. CrossRef
Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
Hao Chen, Nobuyuki Horita, Kentaro Ito, Hideyuki Nagakura, Yu Hara, Nobuaki Kobayash, Masaki Yamamoto, Makoto Kudo, Takeshi Kaneko
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
A Retrospective Cohort Study on Pretreated Neutrophil-to-Lymphocyte Ratio and Prognosis of Small Cell Lung Cancer: Evidence of Effect Modification by Chemotherapy Regimen

Feiwen Liu, Shaozhang Zhou, Liping Tan, Huiqin Jiang, Yucong Huang
Cancer Management and Research.2020; Volume 12: 10341. CrossRef
Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer
Ting Zhou, Zhonghan Zhang, Fan Luo, Yuanyuan Zhao, Xue Hou, Tingting Liu, Kai Wang, Hongyun Zhao, Yan Huang, Li Zhang
JAMA Network Open.2020; 3(10): e2015748. CrossRef
Thérapie ciblée et immunothérapie du cancer bronchique à petites cellules
J.-L. Pujol, C. Goze, C. Pujol, B. Roch
Revue des Maladies Respiratoires Actualités.2019; 11(3): 315. CrossRef
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis
Fei Xu, Xiaoli Ren, Yuan Chen, Qianxia Li, Ruichao Li, Yu Chen, Shu Xia
BMC Cancer.2018;[Epub] CrossRef
Traitement médical du cancer bronchique à petites cellules : peut-on sortir de l’aire du cisplatine–étoposide ?
Jean-Louis Pujol, Benoît Roch, Camille N. Pujol, Catherine Goze
Bulletin du Cancer.2018;[Epub] CrossRef

15,261 View
536 Download
34 Web of Science
29 Crossref

East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL): Keunchil Park, Joo-Hang Kim, Eun Kyung Cho, Jin-Hyoung Kang, Jin-Yuan Shih, Annamaria Hayden Zimmermann, Pablo Lee, Ekaterine Alexandris, Tarun Puri, Mauro Orlando; Cancer Res Treat. 2016;48(4):1177-1186. Published online February 22, 2016; DOI: https://doi.org/10.4143/crt.2015.401

Abstract PDF PubReader ePub

Purpose
REVEL demonstrated improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with docetaxel+ramucirumab versus docetaxel+placebo in 1,253 intent-to-treat (ITT) stage IV non-small cell lung cancer patients with disease progression following platinum-based chemotherapy. Results from the East Asian subgroup analysis are reported.
Materials and Methods
Subgroup analyses were performed in the East Asian ITT population (n=89). Kaplan-Meier analysis and Cox proportional hazards regression were performed for OS and PFS, and the Cochran-Mantel-Haenszel test was performed for response rate.
Results
In docetaxel+ramucirumab (n=43) versus docetaxel+placebo (n=46), median OS was 15.44 months versus 10.17 months (hazard ratio [HR], 0.762; 95% confidence interval [CI], 0.444 to 1.307), median PFS was 4.88 months versus 2.79 months (HR, 0.658; 95% CI, 0.408 to 1.060), and ORR was 25.6% (95% CI, 13.5 to 41.2) versus 8.7% (95% CI, 2.4 to 20.8). Due to increased incidence of neutropenia and febrile neutropenia in East Asian patients, starting dose of docetaxel was reduced for newly enrolled East Asian patients (75 to 60 mg/m2, n=24). In docetaxel+ramucirumab versus docetaxel+placebo, incidence of neutropenia was 84.4% versus 72.7% (75 mg/m2) and 54.5% versus 38.5% (60 mg/m2). Incidence of febrile neutropenia was 43.8% versus 12.1% (75 mg/m2) and 0% versus 7.7% (60 mg/m2).
Conclusion

Results
of this subgroup analysis showed a trend favoring ramucirumab+docetaxel for median OS, PFS, and improved ORR in East Asian patients, consistent with ITT population results. Reduction of starting dose of docetaxel in East Asian patients was associated with improved safety.

Citations

Citations to this article as recorded by

Efficacy and outcomes of ramucirumab and docetaxel in patients with metastatic non-small cell lung cancer after disease progression on immune checkpoint inhibitor therapy: Results of a monocentric, retrospective analysis
Samuel A. Kareff, Kunal Gawri, Khadeja Khan, Deukwoo Kwon, Estelamari Rodriguez, Gilberto de Lima Lopes, Richa Dawar
Frontiers in Oncology.2023;[Epub] CrossRef
Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting
Yu Yang Soon, Wesley Furnback, Jin Kim, Po-Ya Chuang, Gordon Chavez, Christina Proescholdt, Cloe Ying Chee Koh
JTO Clinical and Research Reports.2023; 4(11): 100579. CrossRef
Safety and effectiveness of ramucirumab and docetaxel: a single-arm, prospective, multicenter, non-interventional, observational, post-marketing safety study of NSCLC in Japan
Yucherng Chen, Soshi Nagaoka, Taeko Katayose, Nobuyuki Sekine
Expert Opinion on Drug Safety.2022; 21(5): 691. CrossRef
Validity of the Cancer and Aging Research Group Predictive Tool in Older Japanese Patients
Hirotaka Suto, Yumiko Inui, Atsuo Okamura
Cancers.2022; 14(9): 2075. CrossRef
Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan
Yu Kondo, Tomoya Tachi, Takayoshi Sakakibara, Jun Kato, Aki Kato, Takahito Mizuno, Yoshio Miyake, Hitomi Teramachi
Supportive Care in Cancer.2022; 30(8): 6775. CrossRef
Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)
Yuankai Shi, Lin Wu, Xinmin Yu, Puyuan Xing, Yan Wang, Jianying Zhou, Airong Wang, Jianhua Shi, Yi Hu, Ziping Wang, Guangyu An, Yong Fang, Sanyuan Sun, Caicun Zhou, Changli Wang, Feng Ye, Xingya Li, Junye Wang, Mengzhao Wang, Yunpeng Liu, Yanqiu Zhao, Yin
Cancer Communications.2022; 42(12): 1314. CrossRef
The Relevance of Docetaxel-related Febrile Neutropenia to Patient-reported Symptoms and the Quality of Life in Japanese, East Asian (Korean, Taiwanese), and Non-East Asian Patients Based on Post-hoc Analyses of Two Randomized Clinical Trials of Docetaxel
Yukie Omori, Sotaro Enatsu, Alan J.M. Brnabic, Narayan Rajan, Jin-Yuan Shih, Joo-Hang Kim, Keunchil Park, Akira Inoue
Haigan.2019; 59(7): 1140. CrossRef
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer
Mark A. Socinski, Coleman Obasaju, David Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz-Ares, Maurice Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. S
Journal of Thoracic Oncology.2018; 13(2): 165. CrossRef
Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?
Stefano Frega, Laura Bonanno, Valentina Guarneri, Pierfranco Conte, Giulia Pasello
Critical Reviews in Oncology/Hematology.2018; 128: 19. CrossRef
Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials
Chia-Jui Yen, Kei Muro, Tae-Won Kim, Masatoshi Kudo, Jin-Yuan Shih, Keun-Wook Lee, Yee Chao, Sang-We Kim, Kentaro Yamazaki, JooHyuk Sohn, Rebecca Cheng, Yawei Zhang, Polina Binder, Gu Mi, Mauro Orlando, Hyun Cheol Chung
Journal of Global Oncology.2018; (4): 1. CrossRef
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J. Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok
Cancer Research and Treatment.2018; 50(3): 691. CrossRef
The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum
Takumi Fujiwara, Hirotsugu Kenmotsu, Tateaki Naito, Takahisa Kawamura, Nobuaki Mamesaya, Mie Kotake, Haruki Kobayashi, Shota Omori, Kazuhisa Nakashima, Kazushige Wakuda, Akira Ono, Tetsuhiko Taira, Haruyasu Murakami, Katsuhiro Omae, Keita Mori, Masahiro E
Cancer Chemotherapy and Pharmacology.2017; 79(6): 1229. CrossRef
The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer
Valérie Paulus, Virginie Avrillon, Maurice Pérol
Expert Review of Anticancer Therapy.2016; 16(11): 1119. CrossRef
Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer
Helmut H. Popper, Ulrike Gruber-Mösenbacher, Georg Hutarew, Maximilian Hochmair, Gudrun Absenger, Luka Brcic, Leonhard Müllauer, Gerhard Dekan, Ulrike Setinek, Dagmar Krenbek, Michael Vesely, Robert Pirker, Wolfgang Hilbe, Rainer Kolb, Gerald Webersinke,
memo - Magazine of European Medical Oncology.2016; 9(4): 191. CrossRef

18,486 View
478 Download
16 Web of Science
14 Crossref

Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis: Sook-Hee Hong, Yeon-Sil Kim, Ji Eun Lee, In-ho Kim, Seung Joon Kim, Daehee Han, Ie Ryung Yoo, Yang-Guk Chung, Young-Hoon Kim, Kyo-Young Lee, Jin-Hyoung Kang; Cancer Res Treat. 2016;48(3):1110-1119. Published online January 6, 2016; DOI: https://doi.org/10.4143/crt.2015.289

Abstract PDF PubReader ePub

Purpose
The aim of this study was to analyze clinical characteristics of skeletal metastasis in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) and treatment outcomes of continued EGFR tyrosine kinase inhibitor (TKI) therapy in patients presenting with skeletal metastasis progression. Materials and Methods Of the 216 patients treated with EGFR-TKI for management of stage III-IV NSCLC between 2006 and 2012 in Seoul St. Mary’s Hospital, 76 patients with confirmed EGFR-mutated NSCLC with skeletal metastases during therapy were analyzed retrospectively.
Results
Of 76 patients with EGFR mutant lung cancer with skeletal metastasis, 37 patients developed first progressive disease (PD) in skeletal regions. EGFR-TKI was continued in these 37 patients after first PD in skeletal regions. Median time to first PD of skeletal regions was 8.9 months (95% confidence interval [CI], 4.8 to 13.0). Median time of continued EGFR-TKI after first PD of skeletal regions was 8.0 months (95% CI, 2.9 to 13.0) in patients with disease progression of preexisting regions, 5.6 months (95% CI, 4.5 to 6.7) in patients showing new localized regions, and 3.3 months (95% CI, 1.1 to 5.5) in patients with multiple new metastatic regions (p=0.006). Median time of postskeletal metastasis progression survival was 23.0 months (95% CI, 13.5 to 32.5), 15.0 months (95% CI, 3 to 34.7), and 7.0 months (95% CI, 6.0 to 8.0) (p=0.004) in the above described patient groups, respectively. Overall, seven patients (18.9%) had more than one episode of skeletal progression of disease without extraskeletal PD. Conclusion Continued EGFR-TKI treatment with adequate local treatment after progression of skeletal metastasis may be considered for patients who show disease progression in preexisting regions or local progression.

Citations

Citations to this article as recorded by

From Tumor to Bone: Growth Factor Receptors as Key Players in Cancer Metastasis
Khalid Said Mohammad, Shahid Akhtar Akhund
Frontiers in Bioscience-Landmark.2024;[Epub] CrossRef
Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors
Yue-Yun Chen, Pei-Pei Wang, Yang- Fu, Qing- Li, Jiang-Fang Tian, Ting- Liu, Zhen Lin, Zhen-Yu Ding
Journal of Bone Oncology.2021; 29: 100369. CrossRef
Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value
Xupeng Chai, Eloy Yinwang, Zenan Wang, Zhan Wang, Yucheng Xue, Binghao Li, Hao Zhou, Wenkan Zhang, Shengdong Wang, Yongxing Zhang, Hengyuan Li, Haochen Mou, Lingling Sun, Hao Qu, Fangqian Wang, Zengjie Zhang, Tao Chen, Zhaoming Ye
Frontiers in Oncology.2021;[Epub] CrossRef
Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment
Y. Wang, Y. Li, L. Xia, K. Niu, X. Chen, D. Lu, R. Kong, Z. Chen, J. Sun
Clinical and Translational Oncology.2018; 20(3): 366. CrossRef
Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non‐small‐cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
Xin Li, Han Qi, Gou Qing, Ze Song, Lin Xie, Fei Cao, Xiaoming Chen, Weijun Fan
Thoracic Cancer.2018; 9(8): 1012. CrossRef
Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations
Ming‑Szu Hung, Yu‑Hung Fang, Yu‑Ching Lin, Jr‑Hau Lung, Meng‑Jer Hsieh, Ying‑Huang Tsai
Molecular and Clinical Oncology.2018;[Epub] CrossRef
Risk Factors for Bone Metastasis in Completely Resected Non-Small-Cell Lung Cancer
Hui Wang, Yan Zhang, Hui Zhu, Jinming Yu
Future Oncology.2017; 13(8): 695. CrossRef
Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer
Gino K. In, Jeremy Mason, Sonia Lin, Paul K Newton, Peter Kuhn, Jorge Nieva
Convergent Science Physical Oncology.2017; 3(3): 035002. CrossRef

14,021 View
140 Download
7 Web of Science
8 Crossref

Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy: Jung Ran Choi, Jeong-Oh Kim, Dae Ryong Kang, Jung-Young Shin, Xiang Hua Zhang, Ji Eun Oh, Ji-Young Park, Kyoung-Ah Kim, Jin-Hyoung Kang; Cancer Res Treat. 2015;47(3):509-517. Published online December 16, 2014; DOI: https://doi.org/10.4143/crt.2014.012

Abstract PDF PubReader ePub

Purpose
Dose-limiting toxicities of docetaxel are widely considered to be neutropenia, anemia, skin toxicity, and nausea. One of the factors that limit the use of docetaxel is its unpredictability of inter-individual variation in toxicity. Materials and Methods In order to identify the genetic factors that affect the risk of docetaxel-induced toxicities, we recruited patients who received docetaxel chemotherapy. We genotyped 92 patients with single-nucleotide polymorphisms (SNPs) in 5 genes: CYP3A4 (CYP3A4*1B, CYP3A4*18, and CYP3A4*3), CYP3A5 (CYP3A5*2 and CYP3A5*3), ABCB1 (C1236T, G2677G/T, and C3435T), SLCO1B3 (rs11045585), and ABCC2 (rs12762549). Results Out of 92 patients, 70 had grade 3 or 4 neutropenia; 4 had grade 1 or 2; and 18 had no toxicity (76.1%, 4.3%, and 19.6%, respectively). The findings of the SNP analysis showed that patients with TT genotype of ABCB1 3435C>T polymorphism showed significantly higher risk of neutropenia and anemia (p=0.029 and p=0.044, respectively). There were significant associations between docetaxel-induced leucopenia and 2677G/T of ABCB1 and rs12762549 of ABCC2 (p=0.025 and p=0.028, respectively). In a multivariate analysis, we observed that patients carrying 2677G>T in ABCB1might be associated with higher risk of chemo-resistance when treated with docetaxel (odds ratio [OR], 6.48; confidence interval, 1.92 to 21.94; p=0.003). In a subgroup analysis of non-small cell lung cancer patients, a significant association of tumor response with G2677T/A (OR, 4.54) in ABCB1 and SLCO1B3 (OR, 9.44) was observed. Conclusion Our data suggest that ABCB1 (2677G/T) and SLCO1B3 (rs11055585) might be major genetic predictors of docetaxel-related toxicities in patients receiving docetaxel chemotherapy

Citations

Citations to this article as recorded by

Towards personalized prostate cancer treatment with docetaxel in indonesia: a pharmacogenomics perspective
Jekmal Malau, Siti Rohmah, Nanda Diva Meilani, Anastasia Aliesa Hermosaningtyas, Ahsanal Kasasiah, Ratika Rahmasari, Heri Setiawan, Fahri Azhari Hasby, Muhareva Raekiansyah, Rosario Trijuliamos Manalu
Egyptian Journal of Medical Human Genetics.2025;[Epub] CrossRef
Non-coding RNAs: Emerging contributors to chemoresistance in chronic myeloid leukemia
Laya Ghadyani nejhad, Mahsa Sohani, Nasrin Alizad Ghandforoush, Mohsen Nikbakht, Saeed Mohammadi, Mohammad Vaezi, Shahrbano Rostami, Bahram Chahardouli
Leukemia Research Reports.2025; 23: 100513. CrossRef
Impact of low BMI and ABCC2 genotype on the clinical response of sequential anthracycline-taxane chemotherapy receiving breast cancer patients: a hospital-based study
Tanuma Mistry, Sanghamitra Sengupta, R. Suresh Kumar, Nisha Thakur, Partha Nath, Neyaz Alam, Vilas D. Nasare
The Pharmacogenomics Journal.2025;[Epub] CrossRef
Polymorphism of Transporter Genes Contributes to Variations in Treatment Outcomes and Adverse Events in Platinum Based- Chemotherapy- Treated Oral Cancer Patients
Pranab Kumar Sahoo, Tanuma Mistry, Sushmita Ghosh, Ranita Pal, Sutapa Mahata, Sinjini Sarkar, Trisha Choudhury, Sriparna Datta, R Suresh Kumar, Anup Kumar Bhowmick, Partha Nath, Kalyan Kusum Mukherjee, Vilas D. Nasare
Precision Oncogenomics.2024;[Epub] CrossRef
The Role of Pharmacogenetic-Based Pharmacokinetic Analysis in Precise Breast Cancer Treatment
Xinyu Wu, Huihua Xiong
Pharmaceutics.2024; 16(11): 1407. CrossRef
Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum‐based doublet chemotherapy
Parul Sharma, Navneet Singh, Siddharth Sharma
Journal of Biochemical and Molecular Toxicology.2023;[Epub] CrossRef
Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment
Yoshitaka Saito, Shinya Tamaki, Daisuke Hirate, Shinya Takada, Kenta Takahashi, Yoh Takekuma, Jun Sakakibara-Konishi, Yasushi Shimizu, Ichiro Kinoshita, Mitsuru Sugawara
Scientific Reports.2023;[Epub] CrossRef
Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis
Mingrui Yan, Xiaoyu Fan, Hongyanhua Si, Xiaoyu Wang, Zhe Wang, Zhen Wang, Xin Lv, Hang Yin, Yanyan Jia, Lili Jiang, Yangliu Xia, Yong Liu
Cancer Chemotherapy and Pharmacology.2022; 89(2): 173. CrossRef
Genetic Epidemiology of Medication Safety and Efficacy Related Variants in the Central Han Chinese Population With Whole Genome Sequencing
Junbo Tian, Jing Zhang, Zengguang Yang, Shuaisheng Feng, Shujuan Li, Shiqi Ren, Jianxiang Shi, Xinyue Hou, Xia Xue, Bei Yang, Hongen Xu, Jiancheng Guo
Frontiers in Pharmacology.2022;[Epub] CrossRef
Polymorphisms in solute carrier genes ( SLC19A1 , SLCO1B1 , and SLCO1B3 ) predicts sur
Parul Sharma, Navneet Singh, Siddharth Sharma
Journal of Clinical Pharmacy and Therapeutics.2022; 47(12): 2049. CrossRef
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation
Anne T. Nies, Elke Schaeffeler, Matthias Schwab
Pharmacology & Therapeutics.2022; 238: 108268. CrossRef
Knowledge, attitude, future expectations and perceived barriers of medical students and physicians regarding pharmacogenomics in Jordan
Abdallah Alzoubi, Hashem Kanaan, Dua'a Alhazaimeh, Salam Gharaibeh, Tareq L. Mukattash, Khalid Kheirallah
International Journal of Clinical Practice.2021;[Epub] CrossRef
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel
Caterina Vivaldi, Stefania Crucitta, Silvia Catanese, Federico Cucchiara, Elena Arrigoni, Irene Pecora, Eleonora Rofi, Lorenzo Fornaro, Francesca Salani, Valentina Massa, Enrico Vasile, Riccardo Morganti, Romano Danesi, Marzia Del Re
The Pharmacogenomics Journal.2021; 21(2): 233. CrossRef
Investigation of the 1249G>A Genetic Variation of ABCC2 Drug Transporter Gene in the Turkish Population
Zuhal UCKUN SAHİNOGULLARİ
Dicle Tıp Dergisi.2021; 48(1): 72. CrossRef
Pharmacogenetics–Based Preliminary Algorithm to Predict the Incidence of Infection in Patients Receiving Cytotoxic Chemotherapy for Hematological Malignancies: A Discovery Cohort
Matias F. Martinez, Enzo Alveal, Tomas G. Soto, Eva I. Bustamante, Fernanda Ávila, Shrikant I. Bangdiwala, Ivonne Flores, Claudia Monterrosa, Ricardo Morales, Nelson M. Varela, Alison E. Fohner, Luis A. Quiñones
Frontiers in Pharmacology.2021;[Epub] CrossRef
Genetic associations of docetaxel‐based chemotherapy‐induced myelosuppression in Chinese Han population
Weihua Ren, Chenxi Zhou, Yedong Liu, Keli Su, Li Jia, Luan Chen, Mo Li, Jingsong Ma, Wei Zhou, Suli Zhang, Di Zhang, Zhiliang Cong, Xuecai Niu, Shengui Zhang, Lu Shen, Cong Huai, Xiaofang Sun, Guorong Li, Shengying Qin, Liang Guo
Journal of Clinical Pharmacy and Therapeutics.2020; 45(2): 354. CrossRef
ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy
Hisanaga Nomura, Daiki Tsuji, Ken Demachi, Nobuo Mochizuki, Haruki Matsuzawa, Tomonori Yano, Hiroyuki Daiko, Satoshi Fujii, Takashi Kojima, Kunihiko Itoh, Toshikatsu Kawasaki
Cancer Chemotherapy and Pharmacology.2020; 86(2): 315. CrossRef
Association of a genetic variant in ATP‐binding cassette sub‐family B member 1 gene with poor prognosis in patients with squamous cell carcinoma of the esophagus
Azam Rastgar‐Moghadam, Mehrane Mehramiz, Soodabeh Shahidsales, Malihe Entezari, Seyed Mahdi Hassanian, Sahar Talebian, Mahnaz Nourbakhsh, Gordon A. Ferns, Amir Avan
IUBMB Life.2019; 71(9): 1252. CrossRef
Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology
Rachael R. Schulte, Richard H. Ho
Molecular Pharmacology.2019; 95(5): 490. CrossRef
The Emerging Role of the SLCO1B3 Protein in Cancer Resistance
Ruipu Sun, Ying Ying, Zhimin Tang, Ting Liu, Fuli Shi, Huixia Li, Taichen Guo, Shibo Huang, Ren Lai
Protein & Peptide Letters.2019; 27(1): 17. CrossRef
Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort
Kazuki Sone, Tetsuya Oguri, Takehiro Uemura, Akira Takeuchi, Satoshi Fukuda, Osamu Takakuwa, Ken Maeno, Kensuke Fukumitsu, Yoshihiro Kanemitsu, Hirotsugu Ohkubo, Masaya Takemura, Yutaka Ito, Akio Niimi
BMC Cancer.2019;[Epub] CrossRef
Influence of the ABCB1 polymorphisms on the response to Taxane-containing chemotherapy: a systematic review and meta-analysis
Qi Jiang, Meizhen Xu, Yina Liu, Yudi Chen, Jiarong Feng, Xuelin Wang, Shuang Liang, Dan Li, Xiaoqin Yang
Cancer Chemotherapy and Pharmacology.2018; 81(2): 315. CrossRef
SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand
Raffaele Palmirotta, Claudia Carella, Erica Silvestris, Mauro Cives, Stefania Luigia Stucci, Marco Tucci, Domenica Lovero, Franco Silvestris
Oncotarget.2018; 9(38): 25355. CrossRef
Advances and challenges in hereditary cancer pharmacogenetics
Ingolf Cascorbi, Anneke Nina Werk
Expert Opinion on Drug Metabolism & Toxicology.2017; 13(1): 73. CrossRef
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients
Guillermo Gervasini, Carlos Jara, Clara Olier, Nuria Romero, Ruth Martínez, Juan Antonio Carrillo
British Journal of Clinical Pharmacology.2017; 83(3): 562. CrossRef
Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer
Delmy Oliva, Mats Nilsson, Bengt-Åke Andersson, Lena Sharp, Freddi Lewin, Nongnit Laytragoon-Lewin
Clinical and Translational Radiation Oncology.2017; 2: 1. CrossRef
Reacciones cutáneas a fármacos en el paciente con leucemia/linfoma
Mar Llamas-Velasco, Pedro Rodríguez-Jiménez, Pablo Chicharro, Javier Sánchez-Pérez
Piel.2017; 32(9): 548. CrossRef
Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy
Annelot G.J. van Rossum, Marleen Kok, Danielle McCool, Mark Opdam, Nienke C. Miltenburg, Ingrid A.M. Mandjes, Elise van Leeuwen-Stok, Alex L.T. Imholz, Johanneke E.A. Portielje, Monique M.E.M. Bos, Aart van Bochove, Erik van Werkhoven, Marjanka K. Schmidt
Oncotarget.2017; 8(69): 113531. CrossRef
Efflux Transporter Variants as Predictors of Drug Toxicity in Lung Cancer Patients: Systematic Review and Meta-Analysis
Zoulikha M Zaïr, Donald RJ Singer
Pharmacogenomics.2016; 17(9): 1089. CrossRef
Influx Transporter Variants as Predictors of Cancer Chemotherapy-Induced Toxicity: Systematic Review and Meta-Analysis
Zoulikha M Zaïr, Donald RJ Singer
Pharmacogenomics.2016; 17(10): 1189. CrossRef
Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature
Stefan Wolking, Elke Schaeffeler, Holger Lerche, Matthias Schwab, Anne T. Nies
Clinical Pharmacokinetics.2015; 54(7): 709. CrossRef
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer
Thomas Melchardt, Clemens Hufnagl, Teresa Magnes, Lukas Weiss, Georg Hutarew, Daniel Neureiter, Alexander Schlattau, Gerhard Moser, Alexander Gaggl, Wolfgang Tränkenschuh, Richard Greil, Alexander Egle
BMC Cancer.2015;[Epub] CrossRef
Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review
C.N. Frederiks, S.W. Lam, H.J. Guchelaar, E. Boven
Cancer Treatment Reviews.2015; 41(10): 935. CrossRef

16,060 View
152 Download
38 Web of Science
33 Crossref

Gemcitabine Plus Platinum Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Analysis: Sang Hoon Chun, Ji Eun Lee, Mi Hee Park, Jin-Hyoung Kang, Young Kyoon Kim, Young-Pil Wang, Jae Kil Park, Hoon-Kyo Kim; Cancer Res Treat. 2011;43(4):217-224. Published online December 27, 2011; DOI: https://doi.org/10.4143/crt.2011.43.4.217

Abstract PDF PubReader ePub

PURPOSE
This study aimed to analyze the efficacy and toxicity of gemcitabine plus platinum chemotherapy for patients aged 70 years or older with advanced non-small-cell lung cancer (NSCLC).
MATERIALS AND METHODS
We reviewed the records of stage IIIB, IV NSCLC patients or surgically inoperable stage II, IIIA NSCLC patients who were aged 70 years or older when treated with gemcitabine (1,250 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) chemotherapy from 2001 to 2010 at Seoul St. Mary's Hospital, Uijeongbu St. Mary's Hospital and St. Vincent's Hospital. Gemcitabine was administered on days 1 and 8, and cisplatin or carboplatin was administered on day 1. Treatments were repeated every 3 weeks for a maximum of 4 cycles.
RESULTS
The median age of the 62 patients was 73.5 years (range, 70 to 84 years). Forty-one (66%) patients exhibited comorbidity. The mean number of treatment cycles was 3.9. The compared average relative dose intensity of gemcitabine plus platinum chemotherapy was 84.8%. The median progression-free survival and overall survival (OS) were 5.0 months and 9.4 months, respectively. Reduced Eastern Cooperative Oncology Group (ECOG) performance status (none vs. > or =1) and weight loss (<5% vs. > or =5%) after treatment were found to have a significant effect on OS (p=0.01).
CONCLUSION
Gemcitabine plus platinum chemotherapy is an effective treatment option with an acceptable level of toxicity in patients aged 70 years or older with good performance status in advanced NSCLC.

Citations

Citations to this article as recorded by

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
Xue-Song Sun, Xiao-Hao Wang, Sai-Lan Liu, Dong-Hua Luo, Rui Sun, Li-Ting Liu, Shan-Shan Guo, Qiu-Yan Chen, Lin-Quan Tang, Hai-Qiang Mai
Frontiers in Oncology.2020;[Epub] CrossRef
The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer
Yui Tomita, Toshiaki Saito, Masao Okadome, Takako Eto, Kazuya Ariyoshi, Kumi Shimamoto
International Journal of Clinical Oncology.2014; 19(4): 662. CrossRef
A cross-country review of data collected on non-small cell lung cancer (NSCLC) patients in cancer registries, databases, retrospective and non-randomized prospective studies
Anna De Geer, Jennifer Eriksson, Henrik W. Finnern
Journal of Medical Economics.2013; 16(1): 134. CrossRef
Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Anandi Sawant, Jessy Deshane, Joel Jules, Carnella M. Lee, Brittney A. Harris, Xu Feng, Selvarangan Ponnazhagan
Cancer Research.2013; 73(2): 672. CrossRef
Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways
Anandi Sawant, Cara C. Schafer, Tong Huan Jin, Jaroslaw Zmijewski, Hubert M. Tse, Justin Roth, Zhihuan Sun, Gene P. Siegal, Victor J. Thannickal, Stefan C. Grant, Selvarangan Ponnazhagan, Jessy S. Deshane
Cancer Research.2013; 73(22): 6609. CrossRef

13,109 View
65 Download
5 Crossref

Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer: Dong-Soo Lee, Yeon-Sil Kim, Jin-Hyoung Kang, Sang-Nam Lee, Young-Kyoun Kim, Myung-Im Ahn, Dae-Hee Han, Ie-Ryung Yoo, Young-Pil Wang, Jae-Gil Park, Sei-Chul Yoon, Hong-Seok Jang, Byung-Oak Choi; Cancer Res Treat. 2011;43(1):32-41. Published online March 31, 2011; DOI: https://doi.org/10.4143/crt.2011.43.1.32

Abstract PDF PubReader ePub

PURPOSE
To evaluate treatment outcomes and prognostic factors in non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiation.
MATERIALS AND METHODS
From January 2005 to June 2009, 51 patients were treated with concurrent chemoradiation for 3 different aims: locally advanced stage III, locally recurrent disease, and postoperative gross residual NSCLC. Median age was 63 years. Distribution of stages by the 6th edition of American Joint Committee on Cancer (AJCC) was as follows: IIIA (37.3%), IIIB (56.9%). Chemotherapy was administered every week concurrently with radiation using one of the following regimens: paclitaxel (60 mg/m2), docetaxel+cisplatin (20 mg/m2+20 mg/m2), cisplatin (30 mg/m2). Total radiation dose was 16-66.4 Gy (median, 59.4 Gy).
RESULTS
Median follow-up duration was 40.8 months. The overall response rate was 84.3% with 23 complete responses. The median survival duration for the overall patient group was 17.6 months. The 3-year survival rate was 17.8%. A total of 21 patients had recurrent disease at the following sites: loco-regional sites (23.6%), distant organs (27.5%). In the multivariate analysis of the overall patient group, a clinical tumor response (p=0.002) was the only significant prognostic factor for overall survival (OS). In the multivariate analysis of the definitive chemoradiation arm, the use of consolidation chemotherapy (p=0.022), biologically equivalent dose (BED)10 (p=0.007), and a clinical tumor response (p=0.030) were the significant prognostic factors for OS.The median survival duration of the locally recurrent group and the postoperative gross residual group were 26.4 and 23.9 months, respectively.
CONCLUSION
Our study demonstrated that clinical tumor response was significantly associated with OS in the overall patient group. Further investigations regarding the optimal radiation dose in the definitive chemoradiation and the optimal treatment scheme in locally recurrent NSCLC would be required.

Citations

Citations to this article as recorded by

Unraveling the Impact of Sarcopenia-Induced Lymphopenia on Treatment Response and Prognosis in Patients with Stage III Non–Small Cell Lung Cancer: Insights for Optimizing Chemoradiation and Immune Checkpoint Inhibitor
Joongyo Lee, Kyung Hwan Kim, Jina Kim, Chang Geol Lee, Jaeho Cho, Hong In Yoon, Yeona Cho
Cancer Research and Treatment.2025; 57(2): 422. CrossRef
A scoping review on population-centered indicators for cancer care continuum
Vasuki Rajaguru, Jieun Jang, Jeoung A. Kwon, Jae Hyun Kim, Jaeyong Shin, Mison Chun
Frontiers in Public Health.2022;[Epub] CrossRef
Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases
Lipin Liu, Nan Bi, Zhe Ji, Junling Li, Jingbo Wang, Xiaozhen Wang, Zhouguang Hui, Jima Lv, Jun Liang, Zongmei Zhou, Yan Wang, Weibo Yin, Luhua Wang
BMC Cancer.2015;[Epub] CrossRef
Treatment-related Lymphopenia in Patients With Stage III Non-Small-Cell Lung Cancer
Jian L. Campian, Xiaobu Ye, Malcolm Brock, Stuart A. Grossman
Cancer Investigation.2013; 31(3): 183. CrossRef
Does Pneumonectomy Have a Role in the Treatment of Stage IIIA Non-Small Cell Lung Cancer?
Asad A. Shah, Mathias Worni, Christopher R. Kelsey, Mark W. Onaitis, Thomas A. D'Amico, Mark F. Berry
The Annals of Thoracic Surgery.2013; 95(5): 1700. CrossRef
Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy
Gangjun Du, Yingming Yang, Yaping Zhang, Ting Sun, Weijie Liu, Yingying Wang, Jiahuan Li, Houyun Zhang
Cancer Chemotherapy and Pharmacology.2013; 71(4): 893. CrossRef

12,507 View
68 Download
6 Crossref

Influence of Reduced Folate Carrier and Dihydrofolate Reductase Genes on Methotrexate-Induced Cytotoxicity: Seong-Ae Yoon, Jung Ran Choi, Jeong-Oh Kim, Jung-Young Shin, XiangHua Zhang, Jin-Hyoung Kang; Cancer Res Treat. 2010;42(3):163-171. Published online September 30, 2010; DOI: https://doi.org/10.4143/crt.2010.42.3.163

Abstract PDF PubReader ePub

Purpose

The aim of this study is to investigate the effect of genetic variations and the expression of the reduced folate carrier (RFC) and dihydrofolate reductase (DHFR) on the drug sensitivity to methotrexate (MTX) in different cancer cell lines.

Materials and Methods

We examined the six human cancer cell lines (MCF-7, AGS, A549, NCI-H23, HCT-116 and Saos-2). The cytotoxicity of MTX was measured by sulforhodamine B (SRB) assay. The expressions of the DHFR and RFC were evaluated by real-time PCR and western blotting. Four single nucleotide polymorphisms (SNPs) of the DHFR and two SNPs of the RFC were genotyped.

Results

The IC₅₀s of MTX was in an extensively broad range from 6.05±0.81 nM to>1,000 nM in the cell lines. The Saos-2 (>1,000 nM) and MCF-7 (114.31±5.34 nM) cells were most resistant to MTX; in contrast, the AGS and HCT-116 cells were highly sensitive to MTX with an IC₅₀ of 6.05±0.81 nM and 13.56±3.76 nM, respectively. A reciprocal change of the RFC and DHFR mRNA expression was found between the MTX-sensitive AGS and MTX-resistant Saos-2 cells. There was no significant difference in the expression levels of RFC protein in both the AGS and Saos-2 cells, whereas DHFR protein was more increased in the MTX-resistant Saos-2 cells treated with MTX. The genotype of the MTX-sensitive AGS cells were mutant variants of the DHFR; in contrast, the Saos-2 cells had the wild-type of the DHFR.

Conclusion

In conclusion, this study showed that inverse change of the RFC and DHFR mRNA and protein expression was associated with RFC and DHFR polymorphisms and it is postulated that this phenomenon might play an important role in sensitivity of certain cancers to MTX.

Citations

Citations to this article as recorded by

Synthesis and In Vitro Pharmacological Evaluation of 5,8-Dideaza Analogs of Methotrexate
Marta Abellán-Flos, Charles Skarbek, Dáire J. Gibbons, Estelle Rascol, Ainhoa García, Raphaël Labruère
Molecules.2025; 30(13): 2772. CrossRef
Evaluating the efficacy of bilosomes as a promising nanovector for methotrexate against breast cancer
Aliaa A. Abd-Elfadel, Mohamed Gamal El-Din Ewees, Heba M. Aboud, Waleed M.A. El Rouby, Ahmed A. Farghali, Mohamed I. Zanaty
Journal of Drug Delivery Science and Technology.2025; 113: 107395. CrossRef
A pH-responsive prodrug biomimetic nanoplatform based on cis-aconitic anhydride-modified methotrexate for targeting therapy of oral squamous cell carcinoma
Lin Yang, Yongxiang Zeng, Na Wu, Wei Wu, Liang Chen, Li Zhu
Chemical Engineering Journal.2025; 525: 170412. CrossRef
Non-uniformity in in vitro drug-induced cytotoxicity as evidenced by differences in IC50 values – implications and way forward
T. Arokia Femina, V. Barghavi, K. Archana, N.G. Swethaa, Ravi Maddaly
Journal of Pharmacological and Toxicological Methods.2023; 119: 107238. CrossRef
Cluster of resistance-inducing genes in MCF-7 cells by estrogen, insulin, methotrexate and tamoxifen extracted via NMF
Angelina Boccarelli, Nicoletta Del Buono, Flavia Esposito
Pathology - Research and Practice.2023; 242: 154347. CrossRef
Methotrexate-Induced Subacute Combined Degeneration in Acute Lymphoblastic Leukemia with CNS Relapse May Be Reversible
David Bared Dukenik, Deborah Soong, Wenhui Li, Ellen Madarang, Justin Watts, Justin Taylor
Hemato.2023; 4(4): 311. CrossRef
Associations Between Genetic Polymorphisms Within Transporter Genes and Clinical Response to Methotrexate in Chinese Rheumatoid Arthritis Patients: A Pilot Study
Han Cen, Qin-Wen Wen, Han-Qing Zhang, Hang Yu, Zhen Zeng, Ting Jin, Ting-Hui Wang, Wen Qin, Hua Huang, Xiu-Di Wu
Pharmacogenomics and Personalized Medicine.2022; Volume 15: 327. CrossRef
Development and Optimization of Methotrexate Encapsulated Polymeric Nanocarrier by Ionic Gelation Method and its Evaluations
Rinki Verma, Manoj Kumar
ChemistrySelect.2022;[Epub] CrossRef
Preparation, characterization and in vitro antitumor activity evaluation of hyaluronic acid-alendronate-methotrexate nanoparticles
Chunxia Gao, Mengmeng Wang, Peizhi Zhu, Caifeng Yan
International Journal of Biological Macromolecules.2021; 166: 71. CrossRef
Auger electron therapy of glioblastoma using [125I]5-iodo-2′-deoxyuridine and concomitant chemotherapy – Evaluation of a potential treatment strategy
Karina Lindbøg Madsen, Anne Sofie Nautrup Therkelsen, Niels Langkjær, Birgitte Brinkmann Olsen, Helge Thisgaard
Nuclear Medicine and Biology.2021; 96-97: 35. CrossRef
Thermosensitive hydrogel for in situ-controlled methotrexate delivery
Teresa Darlen Carrillo-Castillo, Antonia Luna-Velasco, Erasto Armando Zaragoza-Contreras, Javier Servando Castro-Carmona
e-Polymers.2021; 21(1): 910. CrossRef
Process optimization by response surface methodology for preparation and evaluation of methotrexate loaded chitosan nanoparticles
N. Raghavendra Naveen, Mallesh Kurakula, Buduru Gowthami
Materials Today: Proceedings.2020; 33: 2716. CrossRef
The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma
Cristina Kinahan, Michael A. Mangone, Luigi Scotto, Michele Visentin, Enrica Marchi, Hearn Jay Cho, Owen A. O’Connor
Oncotarget.2020; 11(18): 1576. CrossRef
Omega-3 offers better hypothalamus protection by decreasing POMC expression and elevating ghrelin hormone: a prospective trial to overcome methotrexate-induced anorexia
Heba Mostafa, Lamia Barakat, Walied S. Abdo, Rania M. Khalil
Endocrine.2020; 69(2): 358. CrossRef
Cellular Analysis and Chemotherapeutic Potential of a Bi-Functionalized Halloysite Nanotube
Yangyang Luo, Ahmed Humayun, Teresa A. Murray, Benjamin S. Kemp, Antwine McFarland, Xuan Liu, David K. Mills
Pharmaceutics.2020; 12(10): 962. CrossRef
Synthesis, In Silico Prediction and In Vitro Evaluation of Antitumor Activities of Novel Pyrido[2,3-d]pyrimidine, Xanthine and Lumazine Derivatives
Samar El-Kalyoubi, Fatimah Agili
Molecules.2020; 25(21): 5205. CrossRef
Recent Advances and Developments ofin vitroEvaluation of Heterocyclic Moieties on Cancer Cell Lines
Runjhun Tandon, Iqubal Singh, Vijay Luxami, Nitin Tandon, Kamaldeep Paul
The Chemical Record.2019; 19(2-3): 362. CrossRef
Methotrexate induces astrocyte apoptosis by disrupting folate metabolism in the mouse juvenile central nervous system
Yanfei Shao, Biqin Tan, Jing Shi, Qian Zhou
Toxicology Letters.2019; 301: 146. CrossRef
PEGAylated graphene oxide/superparamagnetic nanocomposite as a high-efficiency loading nanocarrier for controlled delivery of methotrexate
Zahra Abdollahi, Asghar Taheri-Kafrani, Seyed Amir Bahrani, Abolghasem Abbasi Kajani
Journal of Biotechnology.2019; 298: 88. CrossRef
Lipidic Liquid Crystalline Cubic Phases and Magnetocubosomes as Methotrexate Carriers
Monika Mierzwa, Adrianna Cytryniak, Paweł Krysiński, Renata Bilewicz
Nanomaterials.2019; 9(4): 636. CrossRef
Actively Targeted and Redox Responsive Delivery of Anticancer Drug by Chitosan Nanoparticles
Elisabetta Mazzotta, Selene De Benedittis, Antonio Qualtieri, Rita Muzzalupo
Pharmaceutics.2019; 12(1): 26. CrossRef
Synthesis and properties of a biodegradable polymer-drug conjugate: Methotrexate-poly(glycerol adipate)
Jiraphong Suksiriworapong, Vincenzo Taresco, Delyan P. Ivanov, Ioanna D. Styliari, Krisada Sakchaisri, Varaporn Buraphacheep Junyaprasert, Martin C. Garnett
Colloids and Surfaces B: Biointerfaces.2018; 167: 115. CrossRef
Methotrexate-Coated Complexes of Plasmid DNA and Polyethylenimine for Gene Delivery
Yukinobu Kodama, Ryo Noda, Kayoko Sato, Hitomi Harasawa, Tomoaki Kurosaki, Hiroo Nakagawa, Tadahiro Nakamura, Takashi Kitahara, Takahiro Muro, Hitoshi Sasaki
Biological and Pharmaceutical Bulletin.2018; 41(10): 1537. CrossRef
Synthesis and in vitro evaluation of pH-sensitive magnetic nanocomposites as methotrexate delivery system for targeted cancer therapy
Juan Wu, Aipeng Deng, Wei Jiang, Renbing Tian, Yewen Shen
Materials Science and Engineering: C.2017; 71: 132. CrossRef
Spatial controlled multistage nanocarriers through hybridization of dendrimers and gelatin nanoparticles for deep penetration and therapy into tumor tissue
Yuchao Fan, Shengxiao Yuan, MengMeng Huo, Arka Sen Chaudhuri, Meihui Zhao, Zhenghong Wu, Xiaole Qi
Nanomedicine: Nanotechnology, Biology and Medicine.2017; 13(4): 1399. CrossRef
WITHDRAWN: A fractional factorial design to study the effect of process variables on preparation of methotrexate loaded chitosan nanoparticles
N Raghavendra Naveen, T S Nagaraja, Chakka Gopinath, S V Gopala Krishna, Buduru Gowthami, S Prasanthi, K Mallikarjuna Rao, T Reddi Soundarya, P Jyothsna, G Poojitha
OpenNano.2017;[Epub] CrossRef
Folate Metabolism Regulates Oligodendrocyte Survival and Differentiation by Modulating AMPKα Activity
Qinjie Weng, Jiajia Wang, Jiaying Wang, Biqin Tan, Jing Wang, Haibo Wang, Tao Zheng, Q. Richard Lu, Bo Yang, Qiaojun He
Scientific Reports.2017;[Epub] CrossRef
Theranostic carbon dots ‘clathrate-like’ nanostructures for targeted photo-chemotherapy and bioimaging of cancer
Sunil Pandey, Ganga Raju Gedda, Mukeshchand Thakur, Mukesh Lavkush Bhaisare, Abou Talib, M. Shahnawaz Khan, Shou-Mei Wu, Hui-Fen Wu
Journal of Industrial and Engineering Chemistry.2017; 56: 62. CrossRef
A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer
Masataka Nakano, Tatsuki Fukami, Saki Gotoh, Miki Nakajima
Journal of Biological Chemistry.2017; 292(12): 4873. CrossRef
The impact of methotrexate on lung inflammatory and apoptotic pathway biomarkers—The role of gallic acid
Mustafa Saygin, Onder Ozturk, Ozlem Ozmen, Ilter Ilhan, Taner Gonca, Nurhan Gumral, Hikmet Orhan, Rahime Aslankoc
Biomedicine & Pharmacotherapy.2016; 84: 1689. CrossRef
Interaction of methotrexate, an anticancer agent, with copper(II) ions: coordination pattern, DNA-cleaving properties and cytotoxic studies
Justyna Nagaj, Paulina Kołkowska, Aleksandra Bykowska, Urszula K. Komarnicka, Agnieszka Kyzioł, Małgorzata Jeżowska-Bojczuk
Medicinal Chemistry Research.2015; 24(1): 115. CrossRef
Boronate Cross‐linked ATP‐ and pH‐Responsive Nanogels for Intracellular Delivery of Anticancer Drugs
Xuejiao Zhang, Katharina Achazi, Rainer Haag
Advanced Healthcare Materials.2015; 4(4): 585. CrossRef
Construction of pH-sensitive lysozyme/pectin nanogel for tumor methotrexate delivery
Liufeng Lin, Wei Xu, Hongshan Liang, Lei He, Shilin Liu, Yan Li, Bin Li, Yijie Chen
Colloids and Surfaces B: Biointerfaces.2015; 126: 459. CrossRef
PEGylated solid lipid nanoparticles: design, methotrexate loading and biological evaluation in animal models
Dipti Kakkar, Shweta Dumoga, Rohit Kumar, Krishna Chuttani, Anil Kumar Mishra
MedChemComm.2015; 6(8): 1452. CrossRef
DHFR-mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: The same outcome of treatment with different doses in sensitive cell lines
Jakub Neradil, Gabriela Pavlasova, Martin Sramek, Michal Kyr, Renata Veselska, Jaroslav Sterba
Oncology Reports.2015;[Epub] CrossRef
Spontaneously-forming spheroids as anin vitrocancer cell model for anticancer drug screening
Maria A. Theodoraki, Celso O. Rezende, Oraphin Chantarasriwong, Adriana D. Corben, Emmanuel A. Theodorakis, Mary L. Alpaugh
Oncotarget.2015; 6(25): 21255. CrossRef
Injectable poly(organophosphazene) hydrogel system for effective paclitaxel and doxorubicin combination therapy
Jung-Kyo Cho, Hyo-Jeong Kuh, Soo-Chang Song
Journal of Drug Targeting.2014; 22(8): 761. CrossRef
Adipose-derived stem cells retain their regenerative potential after methotrexate treatment
Olivia S. Beane, Vera C. Fonseca, Eric M. Darling
Experimental Cell Research.2014; 327(2): 222. CrossRef
Methotrexate-Loaded PEGylated Chitosan Nanoparticles: Synthesis, Characterization, and in Vitro and in Vivo Antitumoral Activity
Juan Chen, Liuqing Huang, Huixian Lai, Chenghao Lu, Ming Fang, Qiqing Zhang, Xuetao Luo
Molecular Pharmaceutics.2014; 11(7): 2213. CrossRef
pH/redox responsive core cross-linked nanoparticles from thiolated carboxymethyl chitosan for in vitro release study of methotrexate
Cheng Gao, Ting Liu, Yinghua Dang, Zhiyan Yu, Wei Wang, Jingjing Guo, Xueqiong Zhang, Guanghua He, Hua Zheng, Yihua Yin, Xiangqi Kong
Carbohydrate Polymers.2014; 111: 964. CrossRef
Electrochemically controlled release of anticancer drug methotrexate using nanostructured polypyrrole modified with cetylpyridinium: Release kinetics investigation
Naader Alizadeh, Ehsan Shamaeli
Electrochimica Acta.2014; 130: 488. CrossRef
Mg–Al layered double hydroxide–methotrexate nanohybrid drug delivery system: Evaluation of efficacy
Jui Chakraborty, Susanta Roychowdhury, Somoshree Sengupta, Swapankumar Ghosh
Materials Science and Engineering: C.2013; 33(4): 2168. CrossRef
Reduced Folate Carrier and Folylpolyglutamate Synthetase, but not Thymidylate Synthase Predict Survival in Pemetrexed-Treated Patients Suffering from Malignant Pleural Mesothelioma
Fabian Mairinger, Claudia Vollbrecht, Iris Halbwedl, Martina Hatz, Elvira Stacher, Christian Gülly, Franz Quehenberger, Susann Stephan-Falkenau, Jens Kollmeier, Andreas Roth, Thomas Mairinger, Helmut Popper
Journal of Thoracic Oncology.2013; 8(5): 644. CrossRef
In vitro antitumor activity of methotrexate via pH-sensitive chitosan nanoparticles
Daniele Rubert Nogueira, Lorena Tavano, Montserrat Mitjans, Lourdes Pérez, M. Rosa Infante, M. Pilar Vinardell
Biomaterials.2013; 34(11): 2758. CrossRef
Injectable poly(organophosphazene)–camptothecin conjugate hydrogels: Synthesis, characterization, and antitumor activities
Jung-Kyo Cho, ChangJu Chun, Hyo-Jeong Kuh, Soo-Chang Song
European Journal of Pharmaceutics and Biopharmaceutics.2012; 81(3): 582. CrossRef
Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma
M. Joerger, A. D. R. Huitema, G. Illerhaus, A. J. M. Ferreri
Leukemia & Lymphoma.2012; 53(10): 1867. CrossRef
Selective N-Alkylation of β-Alanine Facilitates the Synthesis of a Poly(amino acid)-Based Theranostic Nanoagent
Santimukul Santra, J. Manuel Perez
Biomacromolecules.2011; 12(11): 3917. CrossRef
Cell-Specific, Activatable, and Theranostic Prodrug for Dual-Targeted Cancer Imaging and Therapy
Santimukul Santra, Charalambos Kaittanis, Oscar J. Santiesteban, J. Manuel Perez
Journal of the American Chemical Society.2011; 133(41): 16680. CrossRef
The reduced folate carrier-1 (RFC1 696T>C) polymorphism is associated with spontaneously aborted embryos in Koreans
Young Joo Jeon, Yi Seul Choi, HyungChul Rah, Youngsok Choi, Tae Ki Yoon, Dong Hee Choi, Nam Keun Kim
Genes & Genomics.2011; 33(3): 223. CrossRef

15,906 View
156 Download
49 Crossref

Prognostic Role of Rb, p16, Cyclin D1 Proteins in Soft Tissue Sarcomas: Byoung Yong Shim, Jinyoung Yoo, Yeon-Soo Lee, Young Sun Hong, Hoon-Kyo Kim, Jin-Hyoung Kang; Cancer Res Treat. 2010;42(3):144-150. Published online September 30, 2010; DOI: https://doi.org/10.4143/crt.2010.42.3.144

Abstract PDF PubReader ePub

Purpose

The aim of this study was to determine the expressions of Rb, p16, and cyclin D1 in soft tissue sarcomas, and we also wanted to identify the prognostic factors according to the clinicalpathologic features.

Materials and Methods

We reviewed the charts and radiographic films of 66 sarcoma patients. Tissue samples were collected from these patients. Immunochemistry was performed using formalin-fixed, paraffin-embedded tissue samples to examine the expressions of p16, Rb, and cyclin D1 proteins.

Results

The median duration of overall survival was 47.8 months (range, 20.0 to 70.7 months) and the 5 years survival rate was 39%. As for the correlation between the degree of immunohistochemical staining for Rb protein and the histological tumor grades, there was a significant difference with a p-value of 0.019. However, no significant correlation was shown for p16 and cyclin D1. The overall survival duration of the Rb negative group (staining cell <20%) and the heterogeneous group (cell staining 20 to 80%) was 53.5±6.6 months and the overall survival duration of the Rb homogeneous group was 18.3±6.4 months, and there was a significant difference with a p-value of 0.016. However, no significant difference was shown between the survival rate according to the p16 and cyclin D1 expressions. On the multivariate analysis that was done with Rb, p16, the tumor size, grade and site, and patient age, the Rb gene expression was the most significant independent prognostic factor with a risk ratio of 3.01 (p=0.04).

Conclusion

The expression of Rb protein was correlated with the histologic grade and overall survival of patients with soft tissue sarcomas.

Citations

Citations to this article as recorded by

Immunohistochemical Expression of p16 and CDK4 in Soft Tissue Tumors
Mala Sagar, Rita Yadav, Pankaj Deval, Madhu Kumar, Malti K Maurya, Sumaira Qayoom
Cureus.2023;[Epub] CrossRef
Carcinosarcoma, a Rare Malignant Neoplasm of the Pancreas
Jaffar Khan, Liang Cheng, Michael G. House, Shunhua Guo
Current Oncology.2021; 28(6): 5295. CrossRef
Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology
Yu Jin Kim, Mingi Kim, Hyung Kyu Park, Dan Bi Yu, Kyungsoo Jung, Kyoung Song, Yoon-La Choi
Laboratory Investigation.2019; 99(9): 1309. CrossRef
Prognostic significance of p16INK4a alteration in soft tissue sarcomas: A meta-analysis
Gang Lin, Yue Lou
Indian Journal of Cancer.2017; 54(3): 580. CrossRef
GATA3 Expression Is a Poor Prognostic Factor in Soft Tissue Sarcomas
Toshiaki Haraguchi, Hiroaki Miyoshi, Koji Hiraoka, Shintaro Yokoyama, Yukinao Ishibashi, Toshihiro Hashiguchi, Koutaro Matsuda, Tetsuya Hamada, Takahiro Okawa, Naoto Shiba, Koichi Ohshima, Ichiro Aoki
PLOS ONE.2016; 11(6): e0156524. CrossRef
Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?
Elisabetta Pennacchioli, Giulio Tosti, Massimo Barberis, Tommaso M. De Pas, Francesco Verrecchia, Claudia Menicanti, Alessandro Testori, Giovanni Mazzarol
Clinical & Experimental Metastasis.2012; 29(7): 757. CrossRef

11,628 View
65 Download
6 Crossref

Radiation Therapy Combined with (or without) Cisplatin-based Chemotherapy for Patients with Nasopharyngeal Cancer: 15-years Experience of a Single Institution in Korea: Yeon-Sil Kim, Bum-Soo Kim, So-Lyoung Jung, Yeon-Soo Lee, Min-Sik Kim, Dong-Il Sun, Eun-Jung Yoo, Seong-Kwon Mun, Sei-Chul Yoon, Su-Mi Chung, Hoon-Kyo Kim, Seung-Ho Jo, Jin-Hyoung Kang; Cancer Res Treat. 2008;40(4):155-163. Published online December 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.4.155

Abstract PDF PubReader ePub

Purpose

This retrospective study was carried out to evaluate the efficacy and toxicity of radiation therapy (RT) with/without cisplatin-based chemotherapy in nasopharyngeal cancer (NPC).

Materials and Methods

One hundred forty six patients with NPC received curative RT and/or cisplatin-based chemotherapy. Thirty-nine patients were treated with induction chemotherapy (IC), including cisplatin and 5-fluorouracil followed by RT. Another 63 patients were treated with concurrent chemoradiotherapy (CCRT) using cisplatin, and 22 patients were treated with IC followed by CCRT. The remaining 22 patients were treated with RT alone.

Results

One hundred four (80.0%) patients achieved complete response (CR), and 23 (17.7%) patients achieved partial response (PR). The patterns of failure were: locoregional recurrences in 21.2% and distant metastases in 17.1%. Five-year overall survival (OS) and progression free survival (PFS) were 50.7% and 45.0%, respectively. Multivariate Cox stepwise regression analysis revealed CR to chemoradiotherapy to be a powerful prognostic factor for OS. CR to chemoradiotherapy and completion of radiation according to the time schedule were favorable prognostic factors for PFS. A comparison of each treatment group (IC → RT vs. CCRT vs. IC → CCRT vs. RT alone) revealed no significant differences in the OS or PFS. However, subgroup analysis showed significant differences in both OS and DFS in favor of the combined chemoradiotherapy group compared with RT alone, for stage IV and T3-4 tumors. Grade 3-4 toxicities were more common in the combined chemoradiotherapy arm, particularly in the CCRT group.

Conclusions

This study was limited in that it was a retrospective study, much time was required to collect patients, and there were imbalances in the number of patients in each treatment group. Combined chemoradiotherapy remarkably prolonged the OS and PFS in subgroup patients with stage IV or T3-4 NPC.

Citations

Citations to this article as recorded by

Effects of SENP1-induced deSUMOylation of STAT1 on proliferation and invasion in nasopharyngeal carcinoma
Jun Zhang, Guo-lin Tan, Ming Jiang, Tian-sheng Wang, Guo-hui Liu, Shan-shan Xiong, Xiang Qing
Cellular Signalling.2023; 101: 110530. CrossRef
SEPT9, H4C6, and RASSF1A methylation in nasopharyngeal swabs: A reflection of potential minimally invasive biomarkers for early screening of nasopharyngeal cancer
Tai Qian, Zhiwei Zhou, Qiongxia Zhang, Yu-Light Liou, Honghao Zhou
Medicine.2023; 102(50): e36583. CrossRef
MicroRNA-145-5p modulates Krüppel-like factor 5 and inhibits cell proliferation, migration, and invasion in nasopharyngeal carcinoma
Chien-Han Yuan, Wei-Chi Hsu, A.-Mei Huang, Ben-Chih Yuan, I.-Hung Chen, Chia-An Hsu, Rong-Feng Chen, Yih-Min Chu, Hui-Hui Lin, Hung-Lung Ke
BMC Molecular and Cell Biology.2022;[Epub] CrossRef
Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma
Fen Xue, Dan Ou, Xiaomin Ou, Xin Zhou, Chaosu Hu, Xiayun He
Oral Oncology.2022; 134: 106139. CrossRef
Transcription Factor STAT1 Promotes the Proliferation, Migration and Invasion of Nasopharyngeal Carcinoma Cells by Upregulating LINC01160
Jingang Ai, Guolin Tan, Tiansheng Wang, Wei Li, Ru Gao, Yexun Song, Shanshan Xiong, Xiang Qing
Future Oncology.2021; 17(1): 57. CrossRef
RETRACTED ARTICLE: Inhibition of PAD4 enhances radiosensitivity and inhibits aggressive phenotypes of nasopharyngeal carcinoma cells
Hao Chen, Min Luo, Xiangping Wang, Ting Liang, Chaoyuan Huang, Changjie Huang, Lining Wei
Cellular & Molecular Biology Letters.2021;[Epub] CrossRef
DNA methylation biomarkers for nasopharyngeal carcinoma
Baoai Han, Xiuping Yang, Po Zhang, Ya Zhang, Yaqin Tu, Zuhong He, Yongqin Li, Jie Yuan, Yaodong Dong, Davood K. Hosseini, Tao Zhou, Haiying Sun, Edwin Wang
PLOS ONE.2020; 15(4): e0230524. CrossRef
Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Nasopharyngeal Carcinoma Patients after Comprehensive Therapy
Yueli Tian, Khamis Hassan Bakari, Shanshan Liao, Xiaotian Xia, Xun Sun, Chunxia Qin, Yongxue Zhang, Xiaoli Lan
Contrast Media & Molecular Imaging.2018; 2018: 1. CrossRef
MiRNA-34a reversed TGF-β-induced epithelial-mesenchymal transition via suppression of SMAD4 in NPC cells
Guanhong Huang, Ming-yu Du, Hongming Zhu, Nan Zhang, Zhi-Wei Lu, Lu-Xi Qian, Wenjun Zhang, Xiaokang Tian, Xia He, Li Yin
Biomedicine & Pharmacotherapy.2018; 106: 217. CrossRef
Long non-coding RNA n326322 promotes the proliferation and invasion in nasopharyngeal carcinoma
Mingyu Du, Teng Huang, Jing Wu, Jia-Jia Gu, Nan Zhang, Kai Ding, Lu-Xi Qian, Zhi-Wei Lu, Wen-Jun Zhang, Xiao-Kang Tian, Xia He, Li Yin
Oncotarget.2018; 9(2): 1843. CrossRef
The effects of microRNA-98 inhibits cell proliferation and invasion by targeting STAT3 in nasopharyngeal carcinoma
Juying Liu, Wei Chen, Zhenzhang Chen, Jing Wen, Hongliang Yu, Feijiang Wang, Lirong Wu, Xia He
Biomedicine & Pharmacotherapy.2017; 93: 869. CrossRef
GALNT7, a target of miR-494, participates in the oncogenesis of nasopharyngeal carcinoma
Guo-Hui Nie, Liang Luo, Hong-Fang Duan, Xiao-Qing Li, Mei-Jun Yin, Zhao Li, Wei Zhang
Tumor Biology.2016; 37(4): 4559. CrossRef
The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis
Jin Ho Song, Hong-Gyun Wu, Bhum Suk Keam, Jeong Hun Hah, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Hyo Jung Park, Chang Geol Lee, Ki Chang Keum, Jihye Cha, Kwan Ho Cho, Sung Ho Moon, Ji-Yoon Kim, Woong-Ki Chung, Young Taek Oh, Won Taek Kim, Moon-June Ch
Cancer Research and Treatment.2016; 48(3): 917. CrossRef
MicroRNA-15a Inhibits Proliferation and Induces Apoptosis in CNE1 Nasopharyngeal Carcinoma Cells
Kang Zhu, Ying He, Cui Xia, Jing Yan, Jin Hou, Demin Kong, Yeye Yang, Guoxi Zheng
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.2016; 24(3): 145. CrossRef
Functional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma
Hong-Fang Duan, Xiao-Qing Li, Hong-Yi Hu, Yu-Chi Li, Zhi Cai, Xue-Shuang Mei, Peng Yu, Li-Ping Nie, Wei Zhang, Zhen-Dong Yu, Guo-Hui Nie
Tumor Biology.2015; 36(9): 6679. CrossRef
Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy
Seung Hwan Moon, Joon Young Choi, Hwan Joo Lee, Young-Ik Son, Chung-Hwan Baek, Yong Chan Ahn, Myung-Ju Ahn, Keunchil Park, Byung-Tae Kim
Clinical and Experimental Otorhinolaryngology.2015; 8(2): 142. CrossRef
MiR-145, a microRNA targeting ADAM17, inhibits the invasion and migration of nasopharyngeal carcinoma cells
Jing Wu, Li Yin, Ning Jiang, Wen-jie Guo, Jia-jia Gu, Meng Chen, You-you Xia, Jian-zhong Wu, Dan Chen, Jian-feng Wu, De-jun Wang, Dan Zong, Nan Zhang, Kai Ding, Teng Huang, Xia He
Experimental Cell Research.2015;[Epub] CrossRef
miR‐539 induces cell cycle arrest in nasopharyngeal carcinoma by targeting cyclin‐dependent kinase 4
Ling‐yan Lv, Yu‐zhi Wang, Qian Zhang, Hong‐rui Zang, Xing‐jie Wang
Cell Biochemistry and Function.2015; 33(8): 534. CrossRef
Chemotherapy of Head and Neck Cancer
Chang Ki Yeo
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2014; 57(5): 291. CrossRef
MicroRNA‐320a inhibits cell proliferation, migration and invasion by targeting BMI‐1 in nasopharyngeal carcinoma
Xiaoming Qi, Jianqiang Li, Changbo Zhou, Chunlei Lv, Min Tian
FEBS Letters.2014; 588(20): 3732. CrossRef
IMRT with Simultaneous Integrated Boost and Concurrent Chemotherapy for Nasopharyngeal Cancer: Plan Evaluation and Treatment Outcome
J. W. Kim, J. H. Cho, K. C. Keum, J. H. Kim, G. E. Kim, J. Y. Lee, S. K. Kim, C. G. Lee
Japanese Journal of Clinical Oncology.2012; 42(12): 1152. CrossRef
Does the prognosis of nasopharyngeal cancer differ among endemic and non-endemic regions?
Senem Demirci, Serra Kamer, Gulsen Kara, Ozgur Yildirim, Mustafa Esassolak
Acta Oto-Laryngologica.2011; 131(8): 852. CrossRef
miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion
Hongping Xia, Samuel S. Ng, Songshan Jiang, William K.C. Cheung, Johnny Sze, Xiu-Wu Bian, Hsiang-fu Kung, Marie C. Lin
Biochemical and Biophysical Research Communications.2010; 391(1): 535. CrossRef

12,530 View
70 Download
23 Crossref

Treatment Outcome of Cisplatin-based Concurrent Chemoradiotherapy in the Patients with Locally Advanced Nasopharyngeal Cancer: Tae Hee Kim, Yoon Ho Ko, Myung Ah Lee, Bum-soo Kim, So Ryoung Chung, Ie Ryung Yoo, Chan-Kwon Jung, Yeon-Sil Kim, Min Sik Kim, Dong-Il Sun, Young Seon Hong, Kyung Shik Lee, Jin-Hyoung Kang; Cancer Res Treat. 2008;40(2):62-70. Published online June 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.2.62

Abstract PDF PubReader ePub

Purpose

The standard treatment of locally advanced nasopharyngeal cancer is a concurrent chemoradiotherapy (CCRT), and cisplatin has been used as the most popular chemotherapeutic agent. But many different doses and schedules for cisplatin administration such as daily, weekly and 3 week cycles have been proposed. We compared and analyzed the tumor response, the overall survival, the toxicity and the chemotherapy dose intensity in the patients with locally advanced nasopharyngeal cancer who were treated with CCRT.

Materials and Methods

We performed a retrospective study on 55 patients with locally advanced nasopharyngeal cancer, and they were treated with CCRT as a front-line treatment from Jan 1996 to Jun 2007 at Kangnam Saint Mary's Hospital.

Results

The patients had a median age of 53 years (range: 19~75 years). Of the total 55 patients, a 3-week cycle of 100mg cisplatin was administered in 31 patients and 30 mg weekly cisplatin was administered in 24 patients combined with radiotherapy. Twenty one patients had a complete response and four patients had a partial response for a response rate of 71.4% (95% CI: 59.5~83.3) after CCRT and followed by adjuvant chemotherapy. The complete response rates for the 30 mg and 100 mg cisplatin groups were 72.7% (95% CI: 54.9~90.5) and 54.2% (95% CI: 36.7~71.7), respectively (p=0.23). The duration of CCRT in the 100mg cisplatin group was significantly longer than that of the 30mg cisplatin group (11.1±2.9 weeks vs. 9.0±1.2 weeks, p=0.003). The major deviation group, which was defined as prolongation of the radiotherapy duration for more than 2 weeks, had a significantly lower objective response rate than did the non-deviation group (56.3% vs 84.2%, respectively, p=0.002). The major severe toxicities were leucopenia (49.1%), pharyngoesophagitis (49.1%), anorexia (43.6%), nausea (41.8%) and vomiting (40%).

Conclusions

Weekly 30mg cisplatin-based CCRT is a practical, feasible cisplatin schedule for the patients with locally advanced nasopharyngeal cancer in regard to decreasing the interruption of radiation treatment and decreasing the treatment-related acute toxicities.

Citations

Citations to this article as recorded by

A prognostic and predictive model based on deep learning to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma: A retrospective multicenter study
Jiong-Lin Liang, Yue-Feng Wen, Ying-Ping Huang, Jia Guo, Yun He, Hong-Wei Xing, Ling Guo, Hai-Qiang Mai, Qi Yang
Radiotherapy and Oncology.2025; 203: 110660. CrossRef
The Effect of Prolonged Duration of Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma
Yi-Jun Hua, Yan-Feng Ou-Yang, Xiong Zou, Le Xia, Dong-Hua Luo, Ming-Yuan Chen
Frontiers in Oncology.2021;[Epub] CrossRef
Taxane-based Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: Prospective Results from a Non-endemic Cohort
S. Ghosh-Laskar, A. Pilar, K. Prabhash, A. Joshi, J.P. Agarwal, T. Gupta, A. Budrukkar, V. Murthy, M. Swain, V. Noronha, V.M. Patil, P. Pai, D. Nair, D.A. Chaukar, S. Thiagarajan, G. Pantvaidya, A. Deshmukh, P. Chaturvedi, S. Nair, A. D‘Cruz
Clinical Oncology.2019; 31(12): 850. CrossRef
Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study
Zhen Su, Yan-Ping Mao, Jie Tang, Xiao-Wen Lan, Pu-Yun OuYang, Fang-Yun Xie
Tumor Biology.2016; 37(4): 4429. CrossRef
Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: a meta-analysis based on randomized controlled trials
Cheng-run Du, Hong-mei Ying, Fang-fang Kong, Rui-ping Zhai, Chao-su Hu
Radiation Oncology.2015;[Epub] CrossRef
Concurrent Chemotherapy for T4 Classification Nasopharyngeal Carcinoma in the Era of Intensity-Modulated Radiotherapy
Cai-neng Cao, Jing-wei Luo, Li Gao, Jun-lin Yi, Xiao-dong Huang, Kai Wang, Shi-ping Zhang, Yuan Qu, Su-yan Li, Jian-ping Xiao, Zhong Zhang, Guo-zhen Xu, Riccardo Dolcetti
PLOS ONE.2015; 10(3): e0119101. CrossRef
Controversies in the systemic treatment of Nasopharyngeal carcinoma
Herbert H. Loong, Anthony T.C. Chan
Oral Oncology.2014; 50(9): 785. CrossRef
Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma
Junlin Yi, Xiaodong Huang, Li Gao, Jingwei Luo, Shiping Zhang, Kai Wang, Yuan Qu, Jianping Xiao, Guozhen Xu
Radiation Oncology.2014;[Epub] CrossRef
Factors Predict Prolonged Wait Time and Longer Duration of Radiotherapy in Patients with Nasopharyngeal Carcinoma: A Multilevel Analysis
Po-Chun Chen, Ching-Chieh Yang, Cheng-Jung Wu, Wen-Shan Liu, Wei-Lun Huang, Ching-Chih Lee, Bart O. Williams
PLoS ONE.2014; 9(10): e109930. CrossRef
Pretreatment Epstein-Barr Virus DNA Load and Cumulative Cisplatin Dose Intensity Affect Long-Term Outcome of Nasopharyngeal Carcinoma Treated with Concurrent Chemotherapy: Experience of an Institute in an Endemic Area
Weihong Wei, Zeli Huang, Shaoen Li, Hemei Chen, Guoyi Zhang, Shuxia Li, Weihan Hu, Tao Xu
Oncology Research and Treatment.2014; 37(3): 88. CrossRef
Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: Phase III Randomized Trial
Qiu-Yan Chen, Yue-Feng Wen, Ling Guo, Huai Liu, Pei-Yu Huang, Hao-Yuan Mo, Ning-Wei Li, Yan-Qun Xiang, Dong-Hua Luo, Fang Qiu, Rui Sun, Man-Quan Deng, Ming-Yuan Chen, Yi-Jun Hua, Xiang Guo, Ka-Jia Cao, Ming-Huang Hong, Chao-Nan Qian, Hai-Qiang Mai
JNCI: Journal of the National Cancer Institute.2011; 103(23): 1761. CrossRef
Radiation Therapy Combined with (or without) Cisplatin-based Chemotherapy for Patients with Nasopharyngeal Cancer: 15-years Experience of a Single Institution in Korea
Yeon-Sil Kim, Bum-Soo Kim, So-Lyoung Jung, Yeon-Soo Lee, Min-Sik Kim, Dong-Il Sun, Eun-Jung Yoo, Seong-Kwon Mun, Sei-Chul Yoon, Su-Mi Chung, Hoon-Kyo Kim, Seung-Ho Jo, Jin-Hyoung Kang
Cancer Research and Treatment.2008; 40(4): 155. CrossRef

13,726 View
70 Download
12 Crossref

First
Prev
Page of 1
Next
Last

Search